U.S. CitiesCity-Data Forum Index
Go Back   City-Data Forum > General Forums > Politics and Other Controversies
 [Register]
Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
View detailed profile (Advanced) or search
site with Google Custom Search

Search Forums  (Advanced)
 
Old 07-13-2017, 05:46 PM
 
15,010 posts, read 8,562,829 times
Reputation: 25001

Advertisements

Promising sign for the pharmaceutical industry. Less government red tape and b.s., get more of these drugs needed by the public out there.

https://arstechnica.com/science/2017...a-on-his-drug/

Quote:
In a rare and surprising reversal, the Food and Drug Administration gave Amicus Therapeutics Inc. the greenlight Tuesday to submit its rare-disease drug, Galafold, for an accelerated review process. Thatís despite the agency previously saying that the drug maker needed to run another clinical trial to better evaluate side-effectsówhich it hasnítóbefore the agency would consider reviewing the drug.
Reply With Quote Quick reply to this message

 
Old 07-13-2017, 06:01 PM
 
2,195 posts, read 943,321 times
Reputation: 3019
Not sure if that's a good thing.

Oxycontin got the same accelerated review process.
Reply With Quote Quick reply to this message
Reply
Please update this thread with any new information or opinions. This open thread is still read by thousands of people, so we encourage all additional points of view.

Quick Reply
Message:

Over $104,000 in prizes was already given out to active posters on our forum and additional giveaways are planned!

Go Back   City-Data Forum > General Forums > Politics and Other Controversies
Similar Threads
Follow City-Data.com founder on our Forum or

All times are GMT -6.

© 2005-2018, Advameg, Inc.

City-Data.com - Archive 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 - Top